# US 2022/0017576 A1 · Recombinant foot-and-mouth disease virus with reduced immunosuppression activity, and preparation method and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017576 A1
- Document ID: US20220017576A1
- Status: Published application
- Kind: A1
- Application number: 17/375,203
- Filed: 2021-07-14
- Published: 2022-01-20
- Earliest claimed: 2020-07-14
- Assignees: Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
- Applicants: Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
- Inventors: Haixue ZHENG; Fan YANG; Zixiang ZHU; Xiangle ZHANG; Weijun CAO; Congcong WANG; Kangli LI; Huisheng LIU; Hong TIAN; Keshan ZHANG; Xiangtao LIU
- Web page: https://patentgrep.com/patent/US20220017576A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61K 39/135: Foot- and mouth-disease virus
- A61P 31/14: for RNA viruses
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/525: {Virus}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2770/32121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/32122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/32134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32151: Methods of production or purification of viral material
- C12N 2770/32152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N 2770/32171: Demonstrated in vivo effect
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure belongs to the technical field of biological products for veterinary medicine, and specifically relates to a recombinant foot-and-mouth disease virus (FMDV) with a reduced immunosuppressive activity, a preparation method and use thereof, and a recombinant vaccine strain. According to the present disclosure, it is firstly discovered that FMDV 3B protein has an immunosuppressive function, and key sites for exerting the immunosuppressive function are found. A recombinant FMDV vaccine strain with a lost immunosuppressive function in FMDV 3B protein is constructed by introducing amino acid mutations into three repeated copies of FMDV 3B protein.

## Claims

### Claim 1

(canceled)

### Claim 2

A preparation method of a recombinant FMDV by losing only an immunosuppressive function of FMDV 3B protein.

### Claim 3

(canceled)

### Claim 4

A recombinant FMDV, wherein the amino acids at position 17 of three copies 3B1, 3B2, and 3B3 of the FMDV 3B protein are mutated to polar amino acids using a gene mutation technology, thus removing an immunosuppressive function of a parental FMDV 3B protein.

### Claim 5 (depends on 4)

A recombinant FMDV vaccine strain comprising the recombinant FMDV according to claim 4.

### Claim 6

A preparation method of a recombinant FMDV, comprising the following steps:
(1) constructing a full-length infectious clone of an FMDV;
(2) mutating amino acids at the position 17 of three copies 3B1, 3B2, and 3B3 of a 3B protein to polar amino acids using a gene mutation technology or a gene synthesis technology on the basis of the full-length infectious clone of an FMDV;
(3) transfecting FMDV-sensitive cells with a eukaryotic expression plasmid containing the polar amino acids mutation at the position 17 of the 3B1, 3B2, and 3B3 proteins, to obtain the recombinant FMDV.

### Claim 7 (depends on 6)

A recombinant FMDV prepared by the preparation method according to claim 6.

### Claim 8 (depends on 7)

A recombinant FMDV vaccine strain comprising the recombinant FMDV according to claim 7.

### Claim 9 (depends on 8)

A recombinant FMDV vaccine prepared by the recombinant FMDV vaccine strain according to claim 8.

### Claim 10 (depends on 9)

A method for preparing a medicine for preventing and/or controlling FMD of an animal, comprising steps of using the recombinant FMDV vaccine according to claim 9.

### Claim 11 (depends on 2)

The method according to claim 2, wherein a method for losing the immunosuppressive function of FMDV 3B protein comprises a gene deletion technology, a gene mutation technology, and a gene insertion technology.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the method for losing the immunosuppressive function of FMDV 3B protein comprises deleting or mutating amino acids at the position 17 of three copies 3B1, 3B2, and 3B3 of the FMDV 3B protein.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the amino acids at position 17 of three copies 3B1, 3B2, and 3B3 of the FMDV 3B protein are mutated to polar amino acids using the gene mutation technology.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the amino acids at position 17 of three copies 3B1, 3B2, and 3B3 of the FMDV 3B protein are mutated to glutamate using the gene mutation technology.

### Claim 15 (depends on 4)

The recombinant FMDV according to claim 4, wherein an amino acid sequence of the parental FMDV 3B protein is set forth in SEQ ID NO:4 and SEQ ID NO:7.

### Claim 16 (depends on 15)

The recombinant FMDV according to claim 15, wherein the amino acids at position 17 of three copies 3B1, 3B2, and 3B3 of the FMDV 3B protein are mutated to glutamate.

### Claim 17 (depends on 16)

The recombinant FMDV according to claim 16, wherein an amino acid sequence of the mutated FMDV 3B protein is set forth in SEQ ID NO:2 and SEQ ID NO:6.

### Claim 18 (depends on 6)

The method according to claim 6, wherein the FMDV-sensitive cell is the BHK-21 cell or porcine kidney (IBRS-2) cell.

### Claim 19 (depends on 6)

The method according to claim 6, wherein the amino acid at the position 17 of three copies 3B1, 3B2 and 3B3 of the FMDV 3B protein is all mutated to glutamate.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the FMDV 3B protein has an amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:6.

### Claim 21 (depends on 10)

A method according to claim 10, wherein the animal comprises pig, cow and sheep.
